Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

– ATH434-201 is a randomized, double-blind, placebo-controlled study in early-stage MSA – – Lead clinical development program enrolled 77 participants globally – MELBOURNE, Australia...

Related Keywords

New Zealand ,United States ,California ,Melbourne ,Victoria ,Australia ,San Francisco ,David Stamler ,Remy Bernarda ,Hannah Howlett ,Alterity Therapeutics ,European Commission ,Securities Exchange ,Nasdaq ,System Atrophy National Institute Of Neurological Disorders ,Chief Executive Officer ,Multiple System Atrophy ,System Atrophy ,National Institute ,Neurological Disorders ,Multiple System ,Media Contacts ,Securities Act ,Securities Exchange Act ,Annual Report ,Markets ,